Latest News and Press Releases

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway...

The global fusion proteins market was valued at $32.4 billion in 2024 and is expected to reach $64.9 billion by the end of 2030 at a CAGR of 12.3%

Io Therapeutics announced today data demonstrating effectiveness of its RXR agonist IRX4204 for synergistic killing of HER2+ breast cancer with CAR-T cells

Keiretsu Forum MST and MDB Capital united 150+ investors to improve syndication and exits, and will expand the Investor Summit series nationwide in 2026.

Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows robust anti-tumor activity...

MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...

Avance Clinical has announced the launch of its new Diversity in STEM Scholarships, in Australia and North America.

MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries Prospective clinical data show NexoBrid® removes...

OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation